325 related articles for article (PubMed ID: 28434262)
1. The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.
Tan SF; Pearson JM; Feith DJ; Loughran TP
Expert Opin Ther Targets; 2017 Jun; 21(6):583-590. PubMed ID: 28434262
[TBL] [Abstract][Full Text] [Related]
2. Acid ceramidase is upregulated in AML and represents a novel therapeutic target.
Tan SF; Liu X; Fox TE; Barth BM; Sharma A; Turner SD; Awwad A; Dewey A; Doi K; Spitzer B; Shah MV; Morad SA; Desai D; Amin S; Zhu J; Liao J; Yun J; Kester M; Claxton DF; Wang HG; Cabot MC; Schuchman EH; Levine RL; Feith DJ; Loughran TP
Oncotarget; 2016 Dec; 7(50):83208-83222. PubMed ID: 27825124
[TBL] [Abstract][Full Text] [Related]
3. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.
Tan SF; Dunton W; Liu X; Fox TE; Morad SAF; Desai D; Doi K; Conaway MR; Amin S; Claxton DF; Wang HG; Kester M; Cabot MC; Feith DJ; Loughran TP
J Lipid Res; 2019 Jun; 60(6):1078-1086. PubMed ID: 30962310
[TBL] [Abstract][Full Text] [Related]
4. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.
Morad SA; Levin JC; Tan SF; Fox TE; Feith DJ; Cabot MC
Biochim Biophys Acta; 2013 Dec; 1831(12):1657-64. PubMed ID: 23939396
[TBL] [Abstract][Full Text] [Related]
5. Acid Ceramidase: A Novel Therapeutic Target in Cancer.
Vijayan Y; Lankadasari MB; Harikumar KB
Curr Top Med Chem; 2019; 19(17):1512-1520. PubMed ID: 30827244
[TBL] [Abstract][Full Text] [Related]
6. Acid ceramidase, an emerging target for anti-cancer and anti-angiogenesis.
Cho SM; Kwon HJ
Arch Pharm Res; 2019 Mar; 42(3):232-243. PubMed ID: 30661200
[TBL] [Abstract][Full Text] [Related]
7. Ceramide Analogue SACLAC Modulates Sphingolipid Levels and
Pearson JM; Tan SF; Sharma A; Annageldiyev C; Fox TE; Abad JL; Fabrias G; Desai D; Amin S; Wang HG; Cabot MC; Claxton DF; Kester M; Feith DJ; Loughran TP
Mol Cancer Res; 2020 Mar; 18(3):352-363. PubMed ID: 31744877
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
9. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.
Morad SA; Tan SF; Feith DJ; Kester M; Claxton DF; Loughran TP; Barth BM; Fox TE; Cabot MC
Biochim Biophys Acta; 2015 Jul; 1851(7):919-28. PubMed ID: 25769964
[TBL] [Abstract][Full Text] [Related]
10. C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth.
Flowers M; Fabriás G; Delgado A; Casas J; Abad JL; Cabot MC
Breast Cancer Res Treat; 2012 Jun; 133(2):447-58. PubMed ID: 21935601
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Lee DJ; Zeidner JF
Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
[No Abstract] [Full Text] [Related]
13. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia.
Shallis RM; Bewersdorf JP; Boddu PC; Zeidan AM
Expert Rev Anticancer Ther; 2019 Aug; 19(8):717-729. PubMed ID: 31422721
[No Abstract] [Full Text] [Related]
14. Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials.
Jammal N; Rausch CR; Kadia TM; Pemmaraju N
Expert Opin Emerg Drugs; 2020 Dec; 25(4):491-499. PubMed ID: 33161749
[No Abstract] [Full Text] [Related]
15. Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.
Ung J; Tan SF; Fox TE; Shaw JJP; Vass LR; Costa-Pinheiro P; Garrett-Bakelman FE; Keng MK; Sharma A; Claxton DF; Levine RL; Tallman MS; Cabot MC; Kester M; Feith DJ; Loughran TP
Blood Rev; 2022 Sep; 55():100950. PubMed ID: 35487785
[TBL] [Abstract][Full Text] [Related]
16. Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells.
Morad SA; Messner MC; Levin JC; Abdelmageed N; Park H; Merrill AH; Cabot MC
Cancer Chemother Pharmacol; 2013 Mar; 71(3):635-45. PubMed ID: 23263160
[TBL] [Abstract][Full Text] [Related]
17. Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia.
Bartaula-Brevik S; Lindstad Brattås MK; Tvedt THA; Reikvam H; Bruserud Ø
Expert Opin Investig Drugs; 2018 Apr; 27(4):377-387. PubMed ID: 29611449
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells.
Ortega JA; Arencibia JM; La Sala G; Borgogno M; Bauer I; Bono L; Braccia C; Armirotti A; Girotto S; Ganesan A; De Vivo M
J Med Chem; 2017 Jul; 60(13):5800-5815. PubMed ID: 28603987
[TBL] [Abstract][Full Text] [Related]
19. ACER3 supports development of acute myeloid leukemia.
Chen C; Yin Y; Li C; Chen J; Xie J; Lu Z; Li M; Wang Y; Zhang CC
Biochem Biophys Res Commun; 2016 Sep; 478(1):33-38. PubMed ID: 27470583
[TBL] [Abstract][Full Text] [Related]
20. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
Xu L; Zhang Y; Gao M; Wang G; Fu Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
